Insitro

Insitro, founded in 2018 by Daphne Koller, is a biotechnology company that integrates machine learning with high-throughput biological data to revolutionize drug discovery and development. By creating predictive models from extensive datasets, Insitro aims to decode complex biological processes, thereby accelerating the identification of novel therapeutic targets and enhancing the efficiency of bringing new drugs to market.

The company has attracted significant investment from a diverse group of investors, including Andreessen Horowitz, Arch Venture Partners, Foresite Capital, Canada Pension Plan Investment Board, and Alexandria Venture Investments. As of March 2021, Insitro had raised approximately $643 million in funding.

What sets Insitro apart is its unique approach of combining advanced machine learning techniques with large-scale biological data generation. This integration enables the company to build robust models that predict disease progression and drug responses, addressing challenges such as high failure rates in clinical trials and lengthy drug development timelines. By leveraging AI, Insitro aims to streamline the drug discovery process, making it more efficient and cost-effective.

In the artificial intelligence landscape, Insitro operates within the category of AI-driven drug discovery and development. Their technology applies machine learning algorithms to biological data, facilitating the identification of new therapeutic targets and the development of effective treatments.

For more information, please visit insitro.com.

To claim this startup page, go to the Contact page and send us a message with your full name, startup name, job title, and startup email address. We will review your request and get back to you. Once verified, you can update your startup information.